Jianmin Pharmaceutical Group Co.,Ltd. (600976.SS)
CNY 42.07
(-0.45%)
CNY 42.07
(-0.45%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 371.58 Million | 215.86 Million | 259.18 Million | 125.53 Million | 74.44 Million | 63.59 Million |
| Net Income | 521.45 Million | 405.5 Million | 325.42 Million | 148.68 Million | 92.63 Million | 81.29 Million |
| Depreciation & Amortization | 59.05 Million | 38.82 Million | 28.68 Million | 20.69 Million | 19.54 Million | 19.89 Million |
| Deferred income taxes | -22.34 Million | 769.61 Thousand | -29.43 Million | -32.44 Million | -12.83 Million | -1.16 Million |
| Stock-based compensation | 8.84 Million | 9.44 Million | 10.27 Million | - | - | - |
| Change in working capital | -86.78 Million | -143.48 Million | 6.32 Million | 45.15 Million | 8.35 Million | 11.7 Million |
| Other non-cash items | 105.09 Million | -95.18 Million | -82.08 Million | -88.99 Million | -46.08 Million | -49.3 Million |
| Investing Cash Flow | -180.5 Million | -143.19 Million | 7.5 Million | -164.82 Million | 18.26 Million | -70.75 Million |
| Investments in PPE | -64.5 Million | -67.96 Million | -55.99 Million | -45.58 Million | -69.31 Million | -42.36 Million |
| Acquisitions | 21.81 Million | 242.65 Thousand | 1.14 Million | 62.96 Thousand | 57.25 Thousand | 2.03 Million |
| Investment purchases | -157.97 Million | -41.44 Million | -1.14 Million | -239.23 Million | -5 Million | -40 Million |
| Sales/Maturities of investments | 20.15 Million | 183.8 Million | 36.3 Million | 79.7 Million | 26.77 Million | 51.6 Million |
| Other Investing Activities | -111.16 Million | -217.83 Million | 27.19 Million | 40.21 Million | 65.74 Million | -42.02 Million |
| Financing Cash Flow | -85.69 Million | -189.44 Million | -50.48 Million | -42.52 Million | -31.54 Million | -26.63 Million |
| Debt repayment | -56.94 Million | -126 Million | -20 Million | -28 Million | - | - |
| Dividends payments | -153.39 Million | -123.34 Million | -58.6 Million | -30.67 Million | -31.26 Million | -31.16 Million |
| Common Stock Repurchased | - | - | -38.33 Million | -1.66 Million | - | - |
| Common Stock Issuance | - | - | 38.33 Million | 1.66 Million | - | - |
| Other Financing Activities | 124.64 Million | 60.56 Million | 28.12 Million | 16.61 Million | -286.2 Thousand | 4.53 Million |
| Accounts receivables | -252.66 Million | -302.97 Million | 3.99 Million | -212.79 Million | -164.49 Million | 33.73 Million |
| Accounts payables | 258.7 Million | 299.01 Million | 4.46 Million | 384.39 Million | 156.87 Million | -27.42 Million |
| Inventory | -92.82 Million | -140.28 Million | 9.74 Million | -93.99 Million | 28.8 Million | 6.56 Million |
| Other working capital | -1.00 | 769.61 Thousand | -11.88 Million | -32.44 Million | -12.83 Million | 5.14 Million |
| Cash at beginning of period | 219.33 Million | 279.97 Million | 62.15 Million | 143.96 Million | 82.8 Million | 116.59 Million |
| Cash at end of period | 305.12 Million | 163.2 Million | 278.36 Million | 62.15 Million | 143.96 Million | 82.8 Million |
| Capital Expenditure | -64.5 Million | -67.96 Million | -55.99 Million | -45.58 Million | -69.31 Million | -42.36 Million |
| Effect of forex changes on cash | -19.59 Million | 0.71 | 0.74 | 0.68 | 0.76 | - |
| Net cash flow / Change in cash | 85.78 Million | -116.77 Million | 216.2 Million | -81.81 Million | 61.16 Million | -33.78 Million |
| Free Cash Flow | 307.08 Million | 147.9 Million | 203.19 Million | 79.95 Million | 5.13 Million | 21.23 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 82.25 Million | 139.83 Million | 99.52 Million | 106.33 Million | 521.45 Million | 162.75 Million |
| Depreciation & Amortization | - | 16.34 Million | 16.34 Million | 16.66 Million | 59.05 Million | -18.1 Million |
| Deferred income taxes | - | - | - | 327.78 Million | -22.34 Million | -144.26 Million |
| Stock-based compensation | - | 1.89 Million | - | 8.84 Million | 8.84 Million | -3.45 Million |
| Change in working capital | - | 78.15 Million | - | -336.63 Million | -86.78 Million | 165.82 Million |
| Other non-cash items | 70.14 Million | -9.21 Million | -148.83 Million | -23.09 Million | 105.09 Million | -69.4 Million |
| Investing Cash Flow | -90.48 Million | -56.71 Million | 42.19 Million | 95.95 Million | -180.5 Million | -363.2 Million |
| Investments in PPE | -38.45 Million | -34.31 Million | -17.87 Million | -24.19 Million | -64.5 Million | -11.86 Million |
| Acquisitions | 125.09 Thousand | 903.19 Thousand | 68.88 Thousand | 5.18 Million | 21.81 Million | 14.03 Million |
| Investment purchases | 937.93 Million | -937.93 Million | -2.33 Million | -132.97 Million | -157.97 Million | 815 Million |
| Sales/Maturities of investments | 101.85 Million | 974.64 Million | 2.33 Million | 20.15 Million | 20.15 Million | 4.34 Million |
| Other Investing Activities | -153.89 Million | 280 Million | 57.66 Million | 227.77 Million | -111.16 Million | -1.18 Billion |
| Financing Cash Flow | 47.1 Million | -147.15 Million | 1.72 Million | -37.58 Million | -85.69 Million | 19.72 Million |
| Debt repayment | -56.39 Million | -10 Million | -4.95 Million | -9 Million | -56.94 Million | -3.5 Million |
| Dividends payments | -1.13 Million | -184.07 Million | -905.14 Thousand | -153.39 Million | -153.39 Million | -997.11 Thousand |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -8.15 Million | 30.37 Million | -3.22 Million | 124.81 Million | 124.64 Million | 24.21 Million |
| Accounts receivables | - | -90.14 Million | - | -252.66 Million | -252.66 Million | 224.04 Million |
| Accounts payables | - | - | - | - | 258.7 Million | 3.45 Million |
| Inventory | - | 171.17 Million | - | -92.82 Million | -92.82 Million | -58.22 Million |
| Other working capital | - | -2.88 Million | - | 8.84 Million | -1.00 | -3.45 Million |
| Cash at beginning of period | 173.59 Million | 305.28 Million | 305.12 Million | 123.86 Million | 219.33 Million | 364.8 Million |
| Cash at end of period | 180.77 Million | 186.34 Million | 305.28 Million | 305.12 Million | 305.12 Million | 110.31 Million |
| Capital Expenditure | -38.45 Million | -34.31 Million | -17.87 Million | -24.19 Million | -64.5 Million | -11.86 Million |
| Effect of forex changes on cash | - | - | 1.00 | 22.98 Million | -19.59 Million | -4.34 Million |
| Net cash flow / Change in cash | 7.17 Million | -118.93 Million | 165.49 Thousand | 181.25 Million | 85.78 Million | -254.48 Million |
| Free Cash Flow | 113.95 Million | 79.94 Million | -67.18 Million | 75.71 Million | 307.08 Million | 81.48 Million |
KIRANSY-B
9830
603341
NELCAST
SEMG
EGL